High-dose-rate brachytherapy monotherapy in patients with localized prostate cancer: Dose modelling and optimization using computer algorithms
The objectives of the study was to optimize the therapy regime variables using two models: Response surface methodology (RSM) and Artificial Neural Network (ANN). (Source: Clinical Oncology)
Source: Clinical Oncology - March 14, 2024 Category: Radiology Authors: Kata Dabic-Stankovic, Katarina Rajkovic, Jovan Stankovic, Goran Marosevic, Goran Kolarevic, Bojan Pavicar Tags: Original Article Source Type: research
Component patterns and survival outcomes in patients with mixed malignant ovarian germ cell tumors: a retrospective cohort study
To evaluate the component patterns and risk stratification in patients with mixed malignant ovarian germ cell tumors (mMOGCT). (Source: Clinical Oncology)
Source: Clinical Oncology - March 14, 2024 Category: Radiology Authors: Sijian Li, Rundong Zhang, Xinyue Zhang, Tianyu Zhang, Dongyan Cao, Yang Xiang, Jiaxin Yang Tags: Original Article Source Type: research
National survey of current follow-up protocols for patients treated for endometrial cancer in the UK
The aim of this study was to establish a baseline of national practice for follow up after treatment for endometrial cancer in the UK. (Source: Clinical Oncology)
Source: Clinical Oncology - March 12, 2024 Category: Radiology Authors: Hersha Patel, Karl Drinkwater, Alexandra Stewart Source Type: research
Volumetric response and survival of patients with bulky idh-mutated grade 3 glioma managed with fet-fdg guided integrated boost imrt.
This study audits volumetric response, survival and functional outcomes in this ‘large volume’ subgroup who undergo intensity modulated radiation therapy (IMRT). (Source: Clinical Oncology)
Source: Clinical Oncology - March 12, 2024 Category: Radiology Authors: D. Mills, P. Horsley, V. Venkatasha, M. Back Tags: Original Article Source Type: research
Estimated Absolute Risks from Typical UK Radiotherapy for Early Breast Cancer During 2015 –2023
Purpose: Breast cancer radiotherapy can increase the risks of heart disease, lung cancer and oesophageal cancer due to incidental irradiation of the heart, lungs and oesophagus, respectively [1]. The absolute risks depend on radiation doses received by these organs and on patients ’ pre-existing risk factors [1–3]. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: F. Holt, A. Ivanova, N. Roberts, Z. Wang, D. Dodwell, C. Taylor Source Type: research
Audit of Hypersensitivity Reactions (HSRs) of Patients with Breast Cancer being Treated with Nab-paclitaxel after Severe HSR to Prior Taxane Chemotherapy; is it Safe?
Purpose: Taxanes (docetaxel and paclitaxel) are standard systemic therapies in treating breast and other cancers. Hypersensitivity reactions (HSRs) are reported in about 10% of patients treated with paclitaxel, with severe reactions in 2 –5%, even with pre-medication [1]. There is also up to 90% cross-reactivity between paclitaxel and docetaxel, for patients who experience a HSR [2]. Nanoparticle albumin-bound (nab-)paclitaxel was initially developed with the aim of reducing toxicity [3]. Early clinical trials of nab-paclitaxel re ported lower rates of HSRs [4], but no published data could be found, other than case repor...
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: M. Jaschke, X. Ren, C. Michie Source Type: research
Gut Microbiota Predict Efficacy of Neoadjuvant Systemic Therapy in Patients with Early Breast Cancer
Purpose: The gut microbiome has been shown to influence the efficacy of some systemic anti-cancer therapies. This prospective study explored the ability of the pre-treatment gut microbiome to predict pathological complete response (pCR) in patients receiving neoadjuvant chemotherapy (NACT) for early breast cancer. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: K. Ross, B. Nichols, R. Papadopoulou, M. Macleod, J. Fraser, S. Barrett, K. Teo, E. Mallon, A. Ammar, J. Edwards, J. Evans, K. Gerasimidis, I. Macpherson Source Type: research
Assessing Agreement to the Use of Hormone Replacement Therapy for Breast Cancer Patients Experiencing Menopausal Symptoms
The objective was to capture an overview of perspectives held by professionals engaged in breast cancer management regarding their attitudes to the use of hormone replacement therapy (HRT) and/or topical oestrogen for women with a breast cancer history and menopausal symptoms. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: A. Ali, A. Branson, P. Bradley Source Type: research
Incidence and Management of Transtuzumab Emtansine- and Transtuzumab Deruxetecan-related Pneumonitis in Breast Cancer Patients within Leicester
Purpose: Antibody drug conjugates (ADC) are an emerging class of therapeutic agent. Transtuzumab emtansine (TDM1) was the first ADC approved in HER2-positive metastatic breast cancer in the UK [1] and subsequently in the early disease setting in 2020 [2]. As a result of DESTINY-Breast0 [3] and DESTINY-Breast 03 [4], transtuzumab deruxtecan (TDXd) was approved recently in the second-line metastatic setting. Interstitial lung disease (ILD) is a well-known treatment limiting toxicity of ADC; occurring in 2 –3% and 10–15% of patients receiving TDM1 and TDXd, respectively. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: S. Bhagani, O. Akala Source Type: research
South West Regional Experience of Alpelisib and Fulvestrant in Patients with a PIK3CA Mutation
Purpose: PIK3CA mutations occur in approximately 40% of patients with hormone receptor-positive and human epidermal growth factor 2-negative breast cancers. The SOLAR-1 trial, a randomised phase III placebo controlled trial compared alpelisib, a PIK3CA inhibitor, with fulvestrant to placebo with fulvestrant [1]. At a median follow-up of 20 months, the progression-free survival in patients with a PIK3CA mutation receiving alpelisib and fulvestrant was 11 months compared with 5.7 months in the placebo plus fulvestrant group. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: C. Crocker, J. Mckeon, R. Dacie, M. Amaya Source Type: research
NICE Technology Appraisals in Breast Oncology and the Impact on Cancer Treatment Unit Activity at the Sussex Cancer Network – 10-year Update
Purpose: The welcome development of new systemic anticancer therapies (SACT) has improved the clinical outcomes for people affected by breast cancer [1,2]. At present, 78% of cancer drug appraisal recommendations by NICE are positive [3]. We have reviewed how these changes have impacted visits to our SACT delivery units in the Sussex Cancer Network between 2013 and 2022. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: K. Eremeishvili, R. Simcock, P. Savage Source Type: research
Comparison of Target Volume Coverage and Organs at Risk in Contoured Regional Nodes versus a Field-based Approach in Adjuvant Breast Radiotherapy
Purpose: Regional nodal irradiation (RNI) reduces recurrence in high-risk breast cancer. Despite international contouring guidelines, including the European Society for Radiotherapy and Oncology (ESTRO) consensus to improve target volume delineation [1], many institutions still use conventional field radiotherapy based on anatomical landmarks. We aimed to assess target volume coverage and dose to organs-at-risk (OARs) between volumes created by nodal contouring and anatomical landmarks. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: C. Guo, C. Kane, A. Anderson, M. Lovegrove, S. Needleman Source Type: research
Significance of Complete Metabolic Response to First-line Taxane/Trastuzumab and Pertuzumab for Advanced HER2+ Breast Cancer: a Single Centre Experience
Purpose: To determine the rate of complete metabolic response (CMR) to first-line therapy with a taxane, trastuzumab and pertuzumab for advanced HER2+ breast cancer and to correlate this with progression-free survival (PFS), overall survival (OS) and the development of brain metastases. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: H. McGrath, C. Foran, A. Midgen, G. Chander, B. Thwaites, Z. Kemp, S. Johnston, E. Kipps, M. Parton, N. Turner, A. Okines Source Type: research
The Prognostic Value of Low HER2 Expression on Treatment Outcomes in Metastatic Hormone Receptor-positive Breast Cancer Patients Treated with CDK4/6 Inhibitors and Endocrine Therapy
Purpose: The combination of CDK4/6 inhibitors (CDK4/6i) with endocrine treatment (ET) has significantly improved treatment outcomes in metastatic hormone receptor-positive (HR+) breast cancer (BC) patients. Limited evidence exists regarding the effectiveness of CDK4/6i in HER2-low BC that recently identified as a targetable subtype of breast tumours [1]. This observational study aimed to investigate the impact of low HER2 expression on patient outcomes. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: R. Muhammad, S. Mumtaz, N. Goyal, A. Konstantis Source Type: research
Real-world Data on Safety Outcome with Treatment of Adjuvant Abemaciclib plus Endocrine Therapy in High-risk Early Hormone-positive, HER2-negative Breast Cancer Patients
Purpose: Adjuvant abemaciclib plus endocrine therapy was approved for high-risk early breast cancer patients within the NHS in June 2022, based on the phase III study Monarch E trial demonstrating improved invasive disease-free survival and an acceptable safety profile compared with endocrine therapy alone [1,2]. The aim of our study was to assess the adverse event profile and tolerability of adjuvant abemaciclib/endocrine therapy in real-world clinical practice in comparison to the trial. (Source: Clinical Oncology)
Source: Clinical Oncology - March 8, 2024 Category: Radiology Authors: H. Neralla, K. Herring, A. Stevens, D. Rea, L. Pallan Source Type: research
